BB BIOTECH AG Composizione del portafoglio di BB Biotech al 31 marzo 2021 (in % dei titoli, valori arrotondati) Ionis Pharmaceuticals 8.1% Moderna 7.8% Neurocrine Biosciences 6.3% Argenx SE 5.7% Incyte 5.2% Agios Pharmaceuticals 5.1% Alexion Pharmaceuticals 4.4% Vertex Pharmaceuticals 4.3% Fate Therapeutics 3.9% Macrogenics 3.6% Alnylam Pharmaceuticals 3.5% Radius Health 3.4% Biogen 3.3% Arvinas 3.0% Sage Therapeutics 2.9% Halozyme Therapeutics 2.7% Intra-Cellular Therapies 2.6% Crispr Therapeutics 2.6% Esperion Therapeutics 2.4% Scholar Rock Holding 2.3% Myovant Sciences 2.3% Molecular Templates 2.3% Generation Bio Co. 1.5% Relay Therapeutics 1.5% Exelixis 1.4% Black Diamond Therapeutics 1.2% Essa Pharma 1.2% Nektar Therapeutics 1.2% Revolution Medicines 1.0% Beam Therapeutics 1.0% Mersana Therapeutics 1.0% Kezar Life Sciences 0.6% Homology Medicines 0.4% Wave Life Sciences 0.3% Alder Biopharmaceuticals - CVR 0.1% Totale titoli CHF 4 278.8 mln Altri attivi CHF 4.1 mln Altri impegni CHF (364.4) mln Valore intrinseco CHF 3 918.5 mln -----------------------------------------------------------------------------------------------------------------------
2021-04-23 I servizi di distribuzione di DGAP comprendono informazioni privilegiate, notizie finanza e comunicati stampa.Archivio media al http://www.dgap.de -----------------------------------------------------------------------------------------------------------------------
Lingua: Italiano
Società: BB BIOTECH AG
Schwertstrasse 6
8200 Schaffhausen
Schweiz
Telefono: +41 52 624 08 45
E-mail: info@bbbiotech.com
Internet: www.bbbiotech.ch
ISIN: CH0038389992
Numero di Sicurezza: A0NFN3
Elencati: Regulierter Markt in Frankfurt (Prime Standard); Mailand, SIX
EQS News ID: 1187801
Fine annuncio DGAP News-Service
=------------ 1187801 2021-04-23
Bildlink:
https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=show_t_gif&application_id=1187801&application_name=news(END) Dow Jones Newswires
April 23, 2021 01:01 ET (05:01 GMT)
